4.4 Review

Cyanobacteria-derived peptide antibiotics discovered since 2000

Journal

PEPTIDES
Volume 107, Issue -, Pages 17-24

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.peptides.2018.08.002

Keywords

Cyanobacteria; Depsipeptide; Lipopeptide; Cyclamide; Antibiotic activity; Structure-activity relationship

Funding

  1. National Natural Science Foundation of China (NSFC) [31672530, U1704117]
  2. Doctoral Foundation of Henan University of Science and Technology [4022/13480021]

Ask authors/readers for more resources

Members of cyanobacteria, including Moorea spp., Okeania spp., Lyngbya spp., Schizothrix spp., Leptolyngbya spp., Microcystis spp., Symploca spp., Hassallia sp., Anabaena spp., Planktothrix sp., Tychonema spp., Oscillatoria spp., Tolypothrix sp., Nostoc sp., and Hapalosiphon sp. produce an enormously diverse range of peptide antibiotics with huge potential as pharmaceutical drugs and biocontrol agents following screening of structural analogues and analysis of structure-activity relationships (SAR). The need for novel antibiotic lead compounds is urgent, and this review summarizes 78 cyanobacteria-derived compounds reported since 2000, including 32 depsipeptides, 18 cyclic lipopeptides, 13 linear lipopeptides, 14 cyclamides, and one typical cyclic peptide. The current and potential therapeutic applications of these peptides are discussed, including for SAR, antituberculotic, antifungal, antibacterial, antiviral, and antiparasitic (anti-plasmodial, antitrypanosomal and antileishmanial) activities.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available